Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
93 hedge funds and large institutions have $1.19B invested in Day One Biopharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more capital invested
Capital invested by funds: $1.04B → $1.19B (+$142M)
7% more funds holding
Funds holding: 87 → 93 (+6)
0.14% more ownership
Funds ownership: 82.58% → 82.72% (+0.14%)
29% less call options, than puts
Call options by funds: $2.88M | Put options by funds: $4.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$35.8M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$16.1M |
| 4 |
BlackRock
New York
|
+$12.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPX
Canaan Partners XI
Menlo Park,
California
|
-$57.4M |
| 2 |
DM
Deerfield Management
New York
|
-$52.7M |
| 3 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$17M |
| 4 |
PA
Perceptive Advisors
New York
|
-$9.95M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$6.36M |
DAWN Hedge Fund Activity: Q3 2022 in Review
93 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2022, worth a combined $1.19B — up 14% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new DAWN positions and 17 closed out — a net gain of 7 holders — while 36 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $41.8M. The largest seller was Canaan Partners XI, cutting an estimated $57.4M.
- 93 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2022, up from 87 in Q2 2022.
- Funds reported $1.19B of Day One Biopharmaceuticals stock for Q3 2022, up 14% quarter-over-quarter.
- 24 funds opened new Day One Biopharmaceuticals positions in Q3 2022 and 17 closed out, a net change of +7 holders.
- The largest Day One Biopharmaceuticals buyer in Q3 2022 was Fidelity Investments, an estimated $41.8M added.
- The largest Day One Biopharmaceuticals seller in Q3 2022 was Canaan Partners XI, an estimated $57.4M sold.
Based on aggregated 13F filings for Q3 2022.